Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Antiphospholipid syndrome
Antisynthetase
Aldostérone
Anticorps spécifique des myosites
Aldosterone
Myositis
Anti-interleukin-6
Male
Adult
Acute Kidney Injury/epidemiology/etiology
Lysosomal storage diseases
Deep immune profiling
Dermatomyositis
Female
Cancer
Antibodies
Analyses multidimensionnelles
Cardio-oncology
Anti-Mi2
Anti-drug antibodies
Adjudication
Anti-synthetase syndrome
Interstitial lung disease
Anti-agalsidase antibodies
Biomarker
Inclusion body myositis
Abnormal movement
Autoimmunity
Amyotrophic lateral sclerosis
Skeletal muscle
Biomarqueurs
Mass cytometry
Adeno-associated virus
Arthritis
AAV vectors
Anti-IgE IgG
Outcome measures
Gene therapy
Myopathy
Systems biology
Anti-MDA5 autoantibodies
Anticorps anti-agalsidase
AAV vector
Antisynthétase
Biopsy
IBM
Anémie hémolytique
Inflammation
Idiopathic inflammatory myopathies
AAV humoral immunity
Anti‐mitochondrial antibodies
Data integration
Fabry disease
Antisynthetase syndrome
Immune checkpoint inhibitors
Acid-alpha-glucosidase
Adeno-associated vector
IMNM
Prognosis
Pharmacology
AAV antibody
Inflammatory myopathy
Sphingosine-1-phosphate
Muscle
Immunotherapy
Multidisciplinarity
Biomarkers
Aged
Humans
Polymyositis
Bioelectrical impedance analysis
Assisted communication devices
Adeno-associated virus vector
Autoimmune diseases
Auto-antibodies
Autoantibodies
Antibody responses
Auto-immunité
B cell homeostasis
Myositis and muscle disease
Autoantibody
Animals
Interferon
B-lymphocyte
COVID-19
Myocarditis
Dependovirus/genetics/immunology
Amyotrophy
DM
Auto‐antibodies
Inborn errors of metabolism
Machine learning
Case reports
Middle Aged
Cytokines
Active
Adverse drug reactions
AAV
Adolescence
Agalsidase